Member Info for MrRipley

I was just about to say the same. The door is being held open for them.

That’s actually the pet name my Mrs calls me.

Mine too! Look at that! We have something in common. Hold on…. Am I wyndrum too?

Ahhh the old I’m not really a builder line. I am heading down south soon actually for a contract. Perhaps you fancy a swift pint? I’m guessing yours is a Rose or a shandy is it?

What he’s trying to say is the price could go up….. or the price could go down. It’s an incredible bit of inside info. You read 90p somewhere which also suggests you should learn how to read for a start. Try the RNS button at the top. Maybe give investing a miss until you have a basic grasp of things. And never, ever, listen to Wynbore. That’ll be £6.99 please.

Dr Elliot foster crossing the why no director buys off the list of bashes there in our ongoing game of basher bingo. Doesn’t he know there’s a death spiral coming? Must be made of money.

https://www.genengnews.com/topics/cancer/avacta-sets-up-shop-in-west-london/#:~:text=Avacta%20found%20a%20home%20in,out%20Alastair%20Smith%2C%20Avacta's%20CEO

Interesting article. Posted on twazzer.

Don’t despair pal. The shackles of how will we fund P1b are now gone, we’ve got data to look forward to and shorts don’t think it’s worth the risk anymore. It feels like post fundraise in 2020 when we sat at 95p for an age. Difference here is we have a major piece of news that is globally important if positive. There’s only so long it can languish at this Mcap. You just need to switch off the emotions. The end of 2022 should be good. The first half of 2023 could be great. And this time next year we’ll be taking about the end of/the results from P2. We’ve been an MM/traders play thing for the past 2 years. At some point a major pharma (if trials are a success) will look at us and say that is a x billon firm. Yoink (that’s what they do when they acquire a company. They say yoink. Then run off leaving a big pile of cash). You just have to ignore the short term movements as all of our IIs seem to be doing.

Nice work Detective. How’s the JFK case coming along? Any new leads?

Anyway. My point is I wouldn’t be surprised, considering news is but weeks away and we’re now in a solid cash position, and we’ve had no value assigned to owning a cash generative diagnostics firm, that we will run up into news again. Last time jupiter left it took the breaks off.

Theres a certain MM that appears when Jupiter are about. Berenberg I believe. There’s a couple of very recent former employees who work for them who have left Jupiter so there’s certainly ties. TW also posts on another share tips site and likes articles written by someone who works for Berenberg too. I can’t remember the exact details but there’s plainly a lot of ball washing going on between these people.

And I would have gotten away with it if it wasn’t for you pesky arsenal duckers.

I’ve been saying for an age now it’ll be held down to allow them an exit when the time comes. The past 2 days, with that kind of buying should have signalled a fair rise. The reason I said by Friday is 3 TW articles in quick succession, an absolute torrent of bashing from the dumbnamic duo on Twatter followed by total silence from them today. It was obvious. I’d say they were a few trades short of being out just this morning.

Next prediction. And this one is less likely. Jupiter to appear in a TR1. I know it’s a long shot. But I wouldn’t be surprised since they can guarantee at least some profits at P1a. Hold out for new rampers on Twitter.

Anyway. I’m ov two bang sum knails into stuf.

Going through today. And constant. Come on MMs. Let it go.

Like when you achieved an 80% loss on adv? You didn’t sing about that did you?

Sage trade is a long time bell end of the Always Winning ilk.

“It is perfectly reasonable for the market to want to wait for hard evidence that this works this time around is it not?”

But you said the market is assuming it does work. Now you’re saying it doesn’t know. So does it know or doesn’t it know?

“You also have no ides who is buying or selling.
Your assumptions are baseless.”

Same as you have no idea what value the market will put on successful P1a. What if it comes with a data package, such as side effects or effectiveness? So your assumptions are also baseless. You’ve also stated it’s market conditions holding the SP back coupled with people being cautious, which would suggest nobody is assuming P1a is successful within the SP. You flit from idea to idea so frequently that you constantly contradict yourself. All the while you accuse others of doing the very things you are doing.

Ok… what’s it for?

I’m going to fund the trials of my wonder drug that makes chemo near side effect free and much much more effective than the standard.

Does it work?

Not sure yet but it’s looking positive.

Ok I’ll give you it via a bond. I’m one of the richest people on earth. I’ve got holdings worth billions in many companies and I cling onto them for long periods of time. Id like to be a major holder of your company that will one day potentially be worth hundreds of billions. Sound good?

Yes.

Ok. It’ll cost you 6%.

Superb. We’ve also acquired a profit making diagnostics company so that covers that. We had hoped to do the same via covid but we got had by the ukgov, but hey ho, we’ve got our income stream now anyway.

Ok great. Sign here.

That’s how I’m seeing the situation.
It’s very simple. We improve chemo to an advantageous degree and we’re worth billions. Then hundreds of billions. And this current loan/raise/bond will seem like chicken feed.

Jupiter and Brontë will drop under 0.5 % by end of play Friday. No amount of buying is shifting the SP. They’re being allowed to step out. AIMO

“Thats what I care about. Has the market priced in success or not? Its been flagged for months its going well, so again I ask, why is the SP where it is..”

How well? That’s the question. Inject them with saline solution and they’ll be fine too. Yes the fact it’s ongoing means it must be activating, but how well? Is it just a bit better? Is it the same with less side effects? Is it replicating animal data? We need some knowledge of side effects and we need to get some basic data. That’s what the market is waiting for. Funding is no longer an issue

With that horror breath he can have anyone. One with of that and no amount of skin grafting can bring you back.